HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berger, G. M. B. Articles by Thompson, G. R. Search for Related Content PubMed PubMed Citation Articles by Berger, G. M. B. Articles by Thompson, G. R. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 39, 1046-1054, May 1998
Copyright © 1998 by Lipid Research, Inc.

Original Article

HMG-CoA reductase is not the site of the primary defect in phytosterolemia

Correspondence to: G. M. B. Berger.

Phytosterolemia is an autosomal recessive disorder characterized by the excessive absorption, reduced excretion, and consequent high tissue and plasma levels of plant sterols, by the presence of tendon xanthomas, and by premature atherosclerosis. Low HMG-CoA reductase (HRase) activity and mass have been reported in liver and mononuclear leucocytes and low mRNA levels in liver from phytosterolemic subjects. These results led to the proposal that the primary defect in this condition involves the HRase gene locus. We examined this hypothesis in phytosterolemic subjects and heterozygous parents from four unrelated families. A variable number tandem repeat (VNTR) polymorphism of the HRase gene in the three informative families and a ScrFI restriction fragment length polymorphism (RFLP) within intron 2 of the gene in one of these families, segregated independently of the disease phenotype. Biological parentage was confirmed in the family in whom both polymorphisms failed to segregate with the disorder. These results conclusively exclude the HRase gene locus as the site of the primary defect in phytosterolemia. The study was extended by examining plasma levels of mevalonic acid and lathosterol, both markers of cholesterol biosynthesis, in response to cholestyramine, a bile acid sequestrant that is known to up-regulate HRase. Oral administration of cholestyramine resulted in a substantial (7.7-fold) increase in mevalonic acid levels in two phytosterolemic subjects, compared with a 2.2-fold rise in their obligate heterozygote parents and a 2.3-fold increase in three healthy control subjects. The lathosterol/cholesterol (L/C) ratio showed a quantitatively similar response. Baseline levels of mevalonate and the L/C ratio were low in the phytosterolemic patients in conformity with reports of reduced cholesterol biosynthesis and HRase activity in this disorder.

These functional data provide support for the concept that the primary defect in phytosterolemia does not affect a trans gene locus responsible for the constitutive expression or regulation of HMG-CoA reductase.—Berger, G. M. B., R. J. Pegoraro, S. B. Patel, P. Naidu, L. Rom, H. Hidaka, A. D. Marais, A. Jadhav, R. P. Naoumova, and G. R. Thompson. HMG-CoA reductase is not the site of the primary defect in phytosterolemia. J. Lipid Res. 1998. 39: 1046–1054.

Supplementary key words: sitosterolemia, mevalonic acid, cholestyramine, family linkage studies, HRase gene, cholesterol synthesis, plant sterols, lathosterol

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G.R. Thompson, F. O'Neill, and M. Seed Why some patients respond poorly to statins and how this might be remedied Eur. Heart J., February 1, 2002; 23(3): 200 - 206. [Full Text] [PDF]